Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration by Lemarié, Fanny et al.
Strathprints Institutional Repository
Lemarié, Fanny and Chang, Chun Wai and Blatchford, David and Amor, Rumelo and Norris,
Greg and Tetley, Laurence and McConnell, Gail and Dufès, Christine (2013) Antitumor activity of
the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous
administration. Nanomedicine, 8 (2). pp. 181-192. ISSN 1743-5889
Strathprints is designed to allow users to access the research output of the University of Strathclyde.
Copyright c© and Moral Rights for the papers on this site are retained by the individual authors
and/or other copyright owners. You may not engage in further distribution of the material for any
profitmaking activities or any commercial gain. You may freely distribute both the url (http://
strathprints.strath.ac.uk/) and the content of this paper for research or study, educational, or
not-for-profit purposes without prior permission or charge.
Any correspondence concerning this service should be sent to Strathprints administrator:
mailto:strathprints@strath.ac.uk
http://strathprints.strath.ac.uk/
ISSN 1743-588910.2217/NNM.12.83 © 2013 Future Medicine Ltd Nanomedicine (2013) 8(2), 181–192 181
ReseaRch aRticle
part of
Antitumor activity of the tea polyphenol 
epigallocatechin-3-gallate encapsulated in 
targeted vesicles after intravenous administration
Epigallocatechin-3-gallate (EGCG), the most 
abundant polyphenol in green tea, has been 
extensively studied for its cancer chemopreven-
tive and therapeutic potential against various 
cancer types [1,2]. It has been shown to be a 
potent inducer of cell death and cell-cycle arrest 
in various cancer types in vitro and in vivo via 
different signaling pathways and mechanisms. 
Previous studies demonstrated that it exerts its 
anticancer effect by modulating the activity of 
MAPK, death-associated protein kinase 2, IGF 
receptor, Akt kinase and NF-kB. EGCG has 
also been shown to induce apoptosis via inhi-
bition of VEGF signaling and production of 
hydrogen peroxide [2]. However, the inability 
of this polyphenol to specifically reach tumors 
following intravenous administration limits 
its potential therapeutic use. Furthermore, as 
a result of its poor oral bioavailability, only 
0.1–1.1% of the orally administered EGCG 
dose is able to reach the systemic circulation, 
leading to plasma EGCG concentrations that 
are five- to 50-times lower than those shown to 
exert biological activities in vitro [3]. Given the 
potent antiproliferative properties of EGCG, 
it is highly important to target the delivery of 
this polyphenol specifically to its site of action. 
To remediate this problem, the authors 
proposed to encapsulate EGCG in transferrin 
(Tf)-bearing vesicles. These vesicles are partic-
ularly attractive for selective receptor-mediated 
drug delivery to tumors because of their ability 
to recognize Tf receptors that are overexpressed 
on many types of cancer cells [4,5]. The combi-
nation of Tf ligands with the passive accumula-
tion of particulate delivery systems in tumors 
due to enhanced permeability and retention has 
been widely used in tumor-targeted strategies 
[6,7–12]. The objectives of this study were, there-
fore, to prepare and characterize Tf-bearing 
vesicles encapsulating EGCG and to evaluate 
their therapeutic efficacy in vitro and in vivo 
following intravenous administration.
Materials & methods
 Cell lines & reagents 
EGCG, iron-saturated human Tf and all other 
chemicals were purchased from Sigma–Aldrich 
(Poole, UK). Solulan™ C24 was obtained from 
Amerchol™ (NJ, USA). DMEM, RPMI-1640 
media, fetal bovine serum, l-glutamine and 
penicillin–streptomycin was obtained from 
Invitrogen™ (Paisley, UK). Dialysis tub-
ing (molecular weight cutoff: 1350 Da) was 
obtained from Medicell International (London, 
UK). A431 human epidermoid carcinoma 
and T98G human glioblastoma were pur-
chased from the European Collection of Cell 
Cultures (Salisbury, UK). d-luciferin and 
Bioware® B16-F10-luc-G5 mouse melanoma 
were obtained from Caliper Life Sciences 
(MA, USA).
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 Preparation & characterization of 
Tf-bearing vesicles encapsulating EGCG
Span™ 60 (65 mg), cholesterol (58 mg) and 
Solulan™ C24 (54 mg) were shaken in 2 ml 
EGCG solution (1 mg/ml in glucose 5% 
solution) for 1 h at 60°C, followed by probe 
sonication (Soniprep 150, Fisher Scientific, 
Loughborough, UK) for 2 × 2 min, at 75% of the 
maximal capacity of the sonicator. Tf (12 mg) 
was conjugated to these vesicles (2 ml) by using 
the crosslinker dimethylsuberimidate (24 mg), 
as previously described [7,8]. Unencapsulated 
EGCG was removed by ultracentrifugation, as 
previously described [7]. 
Vesicles were visualized by transmission elec-
tron microscopy on a LEO 912 energy-filtering 
electron microscope (Sigma–Aldrich). Briefly, 
Formvar/carbon-coated 200-mesh copper grids 
were glow discharged and specimens in distilled 
water were dried down with filter paper to a thin 
layer onto the hydrophilic support film. 20 µl 
of 1% aqueous methylamine vanadate stain 
(NanoVan®) was applied and the mixture dried 
down immediately using filter paper. Specimens 
were imaged with a LEO 912 energy filtering 
transmission electron microscope operating at 
120 kV. Contrast-enhanced, zero-loss energy 
filtered digital images were recorded with a 
14 bit/2K charge-coupled device camera.
The amount of EGCG encapsulated in the 
vesicles was quantified by spectrofluorimetry 
(l
ex
: 305 nm; l
em
: 345 nm), using a Varian 
Cary Eclipse spectrof luorometer (Agilent 
Technologies, CA, USA) following the disrup-
tion of vesicles with isopropanol. The amount 
of Tf linked to vesicles was assessed using the 
Lowry method [7]. The size and zeta potential 
of the vesicles were determined through pho-
ton correlation spectroscopy and laser Doppler 
electro phoresis, using a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, UK). 
The release of EGCG from Tf-bearing vesi-
cles was determined by dialysis of 1 ml vesicles 
against 10 ml phosphate-buffered saline at 37°C, 
whilst stirring for 24 h. At different time-points, 
a 1 ml sample of the dialysate was withdrawn and 
immediately replaced with an equal volume of 
fresh solution. The amount of EGCG present in 
the samples was quantified by spectrofluorimetry 
(l
ex
: 305 nm; l
em
: 345 nm).
 In vitro biological characterization
Cell culture
An A431 human epidermoid carcinoma, T98G 
human glioblastoma and B16-F10-luc-G5 
mouse melanoma overexpressing Tf receptors 
were cultured in either DMEM (for A431 and 
T98G cells) or in RPMI-1640 medium (for 
B16-F10-luc-G5 cells), at 37°C in a humidi-
fied atmosphere under 5% CO
2
. Both media 
were supplemented with 10% (v/v) fetal bovine 
serum, 1% (v/v) l-glutamine and 0.5% (v/v) 
penicillin–streptomycin. 
Cellular uptake of EGCG encapsulated in 
Tf-bearing vesicles
A431, T98G and B16-F10 cells were seeded at 
a density of 2 × 103 cells/well in 96-well plates 
and grown for 72 h prior to being treated with 
EGCG (10 µg/well) in solution or encapsulated 
in Tf-bearing or control vesicles. After the 72-h 
treatment, the cells were washed three times 
with phosphate-buffered saline and lyzed. The 
amount of EGCG in the cell lysate was quan-
tified by spectrofluorimetry (l
ex
: 305 nm; l
em
: 
345 nm).
The cellular uptake of EGCG encapsulated 
in Tf-bearing vesicles was also qualitatively ana-
lyzed by coherent anti-Stokes Raman scattering 
microscopy [13]. This novel form of microscopy 
presents the advantage of selectively detecting 
molecules without using any exogenous label. 
A431, T98G and B16-F10 cells were seeded in 
four-well chamber slides (104 cells/well) and 
grown at 37°C for 72 h. They were then treated 
with EGCG (10 µg/well), in solution or encap-
sulated in Tf-bearing or control vesicles. After 
the 24-h treatment, the cells were then washed 
three times with phosphate-buffered saline, fixed 
in methanol for 10 min and rinsed with distilled 
water before being examined using a custom-
built coherent anti-Stokes Raman scattering 
microscope and a previously described technique 
[10,13]. EGCG was detected at 2916 cm-1.
 In vitro antiproliferative activity
A431, T98G and B16-F10 cells were seeded at a 
density of 2 × 103 cells/well in 96-well plates and 
grown for 72 h prior to being treated with freshly 
prepared EGCG formulations at final concentra-
tions of 5 × 10-7 – 2.5 × 101 µg EGCG/ml. After 
the 72-h treatment, antiproliferative activity was 
determined using a standard 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 
(MTT) assay (three independent experiments 
with n = 5 for each concentration level) [8].
 In vivo tumoricidal activity
All animal experiments conducted were approved 
by local ethics committees and performed in 
accordance with the UK Home Office regu-
lations. Female, nonfasting immunodeficient 
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BALB/c mice (initial mean weight: 20 g) were 
housed in groups of five with a room tempera-
ture of 21 ± 2°C and alternating 12-h light–dark 
cycles. A431 or B16-F10-luc-G5 cancer cells 
in exponential growth were subcutaneously 
implanted to both flanks of the mice (1 × 106 
cells per flank). When tumors become palpable 
and reached a diameter of 5 mm, the mice were 
intravenously injected with EGCG encapsu-
lated in Tf-bearing vesicles, control vesicles or 
in solution (10 µg EGCG per injection) once 
daily for 20 days. The mice were observed 
daily for tumor growth and changes in body-
weight. The tumor volume was determined by 
caliper measurements and calculated by the 
formula: volume = d3 × p/6. In accordance 
with the Response Evaluation Criteria in Solid 
Tumors [14], responses to treatment were classi-
fied as follows: progressive disease for relative 
tumor volume higher than 1.2-fold; stable dis-
ease for relative tumor volume between 0.7- and 
1.2-fold; partial response for relative tumor 
volume between 0- and 0.7-fold; and com-
plete response when the tumor has completely 
disappeared. 
Tumor growth was also monitored by bio-
luminescence imaging with an IVIS® Spectrum 
(Caliper Life Sciences). Mice bearing subcuta-
neous B16-F10-luc-G5 tumors were treated 
intravenously as described earlier. In addition, 
10 min prior to in vivo imaging, mice received 
the luciferase substrate d-luciferin (150 mg/kg 
bodyweight) by intraperitoneal injection and 
were anesthetized by isoflurane inhalation on 
days 1, 3, 5, 7 and 9. The light emitted from 
the bioluminescent tumors was detected for 
2 min using Living Image® software (Caliper 
Life Sciences) and displayed as a pseudocolor 
overlay onto a grayscale animal image. 
 Statistical analysis
Results were expressed as mean ± standard error 
of the mean. Statistical significances were calcu-
lated with the one-way analysis of variance test 
followed by the Bonferroni multiple comparison 
post-test using the GraphPad Prism® software 
(GraphPad, CA, USA). P-values lower than 0.05 
were considered statistically different.
Results 
 Preparation & characterization of 
Tf-bearing vesicles encapsulating EGCG
Vesicles encapsulating EGCG and conjugated to 
Tf were prepared. Transmission electron micro-
scopy studies confirmed the spherical shape of 
these delivery systems (Figure 1A). Vesicles were 
able to encapsulate 30.3 ± 2.8% of the initial 
EGCG and were conjugated to 25.7 ± 2.5% of 
the initial Tf. As expected, the conjugation of Tf 
to the surface of vesicles resulted in a larger vesic-
ular size (294 nm; polydispersity: 0.414) than 
that of control vesicles (205 nm; polydispersity: 
0.427). These sizes were nevertheless below the 
cutoff size for extravasation, which was 400 nm 
for most tumors [15,16].
The grafting of Tf to the vesicles reduced their 
zeta potential compared with that of control 
vesicles (-36 and -28 mV, respectively). These 
net negative charges are actually advantageous 
for a delivery system compared with positively 
charged formulations, as they would reduce the 
electrostatic interactions of the vesicles with the 
negatively charged cell membrane and, there-
fore, should decrease the nonspecific uptake of 
the vesicles by the cells [17].
EGCG was released relatively readily from 
Tf-bearing vesicles (Figure 2): approximately 
50% of the drug leaked out of the formula-
tion 6 h after the start of the experiment. The 
release of the drug then reached a plateau from 
10 h. The relatively rapid release, that is, 80% 
of the drug within 24 h, indicated that EGCG 
should be efficiently released from its vesicular 
formulation after localization in the tumor fol-
lowing intravenous administration to induce its 
therapeutic effect. 
 Cellular uptake of EGCG
The cellular uptake of EGCG after treat-
ment with Tf-bearing vesicles was significantly 
increased (by at least 1.5-fold) in comparison 
with control vesicles and the drug solution 
for the three cell lines. It was nearly threefold 
higher when compared with EGCG solution on 
B16-F10 cells (Figures 1B & 1C). The level of drug 
uptake following administration of Tf-bearing 
vesicles was similar to that previously observed 
when using tocotrienol instead of EGCG as the 
carried drug [8]. 
In terms of intracellular distribution, coher-
ent anti-Stokes Raman scattering experiments 
showed that EGCG was either localized in the 
nuclei of A431 cells or disseminated within 
B16-F10 and T98G cells following administra-
tion of Tf-bearing vesicles. By contrast, EGCG 
administered in control vesicles or as a solution 
could not be detected, except in T98G cells after 
administration of control vesicles. This might 
be explained by the image acquisition param-
eters chosen for this qualitative experiment, 
with a threshold probably allowing only higher 
amounts of EGCG to be detected. 
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Figure 1. Preparation and characterization of transferrin-bearing vesicles encapsulating 
epigallocatechin-3-gallate. (A) Transmission electron micrograph confirming the formation of 
vesicles encapsulating EGCG and bearing Tf. (B) Quantification of the cellular uptake of EGCG 
(10 µg/well), either encapsulated in Tf vesicles, control vesicles or free in solution, in A431, B16-F10 
and T98G cell lines (controls: untreated cells; n = 15), respectively. Error bars represent standard 
error of the mean. (C) CARS and transmission microscopy imaging of the cellular uptake of EGCG 
(10 µg/well) either encapsulated in Tf vesicles, control vesicles or free in solution, after incubation 
for 24 h in A431, B16-F10 and T98G cells (controls: untreated cells). All images were taken in the 
size of 512 × 512 pixels and with no averaging, at a frame capture rate of 1.68 s. The pump 
wavelength and the Stokes beam wavelength were tuned to 752.1 and 963.4 nm, respectively, 
corresponding to a Raman shift of 2916 cm-1 where the drug was expected to give the strongest 
CARS signals. 
*p < 0.05. 
CARS: Coherent anti-Stokes Raman scattering; EGCG: Epigallocatechin-3-gallate; Tf: Transferrin.
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 In vitro therapeutic efficacy
The treatment of cells with EGCG encapsulated 
in Tf-bearing vesicles significantly improved the 
in vitro therapeutic efficacy when compared 
with control vesicles by 1.9-fold for A431 cells; 
2.7-fold for B16-F10 cells; and fourfold for 
T98G cells (IC
50
 ranging from 0.36 ± 0.05 to 
1.41 ± 0.17 µg/ml for the Tf-bearing vesicles) 
(Figure 3 & TABle 1). By contrast, EGCG in solu-
tion did not have significant effects on the cell 
viability for the experimental parameters and 
concentrations used; thus, demonstrating that 
a delivery system is necessary for the effective 
delivery of EGCG to cancer cells.
 In vivo tumoricidal activity
The intravenous injection of EGCG encapsulated 
in Tf-bearing vesicles to the mice led to tumor 
regression within 24 h for both tumor types 
(Figures 4 & 5, supplemenTAry Figures 1 & 2, see online 
at www.futuremedicine.com/doi/suppl/10.2217/
nnm.12.83). Most of these tumors continued to 
regress over the following month, leading to the 
complete disappearance of 40% of the A431 and 
B16-F10 tumors on day 30. Following the same 
treatment, 30% of A431 and 20% of B16-F10 
showed a partial response, but did not entirely 
disappear, and 10% of B16-F10 tumors were 
stable. By contrast, all the A431 and B16-F10 
tumors treated with control vesicles, drug 
solution or left untreated continued to grow. 
The therapeutic effect resulting from treat-
ment with EGCG encapsulated in Tf-bearing 
vesicles was also qualitatively confirmed by bio-
luminescence imaging on mice bearing subcuta-
neous B16-F10-luc tumors (Figure 6). Following 
treatment with the Tf-bearing formulation, 
luciferase expression in the tumors gradually 
decreased from day 1 to 7, and disappeared at 
day 9 as a result of the complete eradication of 
the tumor. By contrast, all the other treatments 
led to an increase of luciferase expression in the 
growing tumors. 
This dramatically improved therapeutic 
effect resulted in an extended animal survival 
by day 26 and 25, respectively for mice bear-
ing A431 and B16-F10 tumors, compared with 
untreated mice, with 60% of mice treated with 
Tf-bearing vesicles still being alive at day 30 
(Figures 4D & 5D). The administration of con-
trol vesicles only improved animal survival by 
day 2 and 5, respectively for A431 and B16-F10 
tumors, compared with untreated mice. This 
weak extension was similar to the 2-day 
improvement obtained following administration 
of EGCG solution. 
No significant variation of bodyweight was 
detected, suggesting that all the tested EGCG 
formulations were well tolerated by the animals 
(Figures 4B & 5B). 
Discussion
The possibility of using the green tea polyphenol, 
EGCG, for the treatment of cancer is hampered 
by the inability of this drug to reach tumors in a 
specific way after intravenous administration. On 
the basis that Tf receptors are expressed in abun-
dance on cancer cells, and have been successfully 
used for the tumor targeting of therapeutic drugs 
and genes, the authors  hypothesized that the 
encapsulation of EGCG in Tf-bearing vesicles 
would improve the delivery of this drug to cancer 
cells, leading to better therapeutic efficacy. 
In this study, vesicles encapsulating EGCG 
and bearing Tf were successfully prepared. In 
contrast to that observed with giant unilamellar 
vesicles [18], the encapsulation of EGCG in the 
novel vesicles did not cause any shape change, 
aggregation or bursting of delivery systems. The 
vesicles used in this study were formed in a similar 
manner to liposomes. Their nontargeted counter-
parts have been used previously for the delivery of 
doxorubicin to tumors [19]. They were shown to 
alter the metabolism of this drug and to increase 
its therapeutic index in in vivo experiments. 
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Figure 2. Release of epigallocatechin-3-gallate from transferrin-bearing 
vesicles upon dialysis against phosphate-buffered saline at 37°C. Error bars 
represent standard error of the mean (n = 3).
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The amount of EGCG encapsulated in the 
vesicles was measured by spectrofluorimetry. 
This technique has been used successfully for the 
detection of this drug at an excitation wavelength 
of 280 nm and emission wavelength of 320 nm 
[20]. However, the polyphenol used in this 
experiment was shown to present a maximum 
emission peak at 345 nm following excitation 
at 305 nm. 
Tf-bearing vesicles encapsulating EGCG dis-
played sizes enabling them to extravasate across 
tumor vasculature [15,16] and, therefore, have 
the properties required in order to efficiently 
deliver EGCG to tumors. The polydispersity 
of the vesicles led to smaller vesicles having a 
prolonged circulation time and higher tumor 
accumulation than their larger counterparts 
[15]; thus, highlighting the need to reduce the 
polydispersity and vesicle size in future experi-
ments. EGCG has previously been encapsulated 
in various delivery systems, such as nanoparticles 
[21-24], phosphatidylcholine-based liposomes [25] 
and giant unilamellar vesicles [18]. However, to 
our knowledge, the present study describes, for 
the first time, a formulation of EGCG encapsu-
lated in a tumor-targeted vesicular system. The 
resulting targeted delivery of the drug would 
allow a decrease of the dosage of EGCG needed 
to obtain a therapeutic effect. 
Cellular uptake studies demonstrated that the 
presence of Tf at the surface of the vesicles sig-
nificantly increases EGCG uptake by the three 
cell lines in comparison with control vesicles and 
EGCG solution. These results were in agreement 
with our previous data that showed that the use 
of Tf as a targeting ligand on similar vesicles 
improved the uptake of the drug tocotrienol 
by at least 1.5-fold for the three cell lines tested 
[8]. The nuclear and perinuclear accumulation 
of EGCG displayed in A431 cells treated with 
Tf-bearing formulation was most probably due 
to the cellular uptake of the drug via receptor-
mediated endocytosis, as this uptake mechanism 
has been shown previously to give this pattern of 
drug distribution in the cells [26]. An incubation 
duration of 72 h was chosen in this study to allow 
comparison with the authors’ previous results 
obtained using similar vesicles entrapping the 
polyphenol tocotrienol with the same experimen-
tal settings. As the authors’ future objective is to 
co-entrap these two drugs in the same delivery 
system for a synergistic therapeutic effect, it was 
crucial to keep the experimental parameters of 
the two studies as similar as possible. 
The encapsulation of EGCG in vesicles 
conjugated to Tf significantly improved the 
in vitro therapeutic efficacy of the system 
on the three cancer cell lines studied. These 
IC
50
 values were in the same range as those 
obtained when treating PCa and 22Tv1 pros-
tate cancers with EGCG encapsulated in nano-
particles. In the study of Siddiqui et al., EGCG 
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Figure 3. Cytotoxicity of epigallocatechin-3-gallate, either entrapped in 
transferrin vesicles, control vesicles or free in solution in three cancer cell 
lines. (A) A431 cells; (B) B16-F10 cells; and (C) T98G cells. The cytotoxicity was 
expressed as IC
50
 values (n = 15). Error bars represent standard error of the mean.
EGCG: Epigallocatechin-3-gallate; Tf: Transferrin.
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nanoparticles (IC
50
: 1.71 µg/ml) presented a ten-
fold dose advantage compared with free EGCG 
(IC
50
: 19.9 µg/ml) on human prostate cancer 
cells [24]. However, the relative therapeutic effect 
of Tf-bearing vesicles encapsulating EGCG 
appears to be further improved in the three cell 
lines, given that the free drug was not able to 
kill the cancer cells at the tested concentrations 
and experimental parameters. These results may 
be attributed to the enhanced cellular uptake of 
EGCG when encapsulated in Tf-bearing vesicles. 
Although this uptake was similar for the three 
cell lines, the in vitro therapeutic effect was 
more pronounced in T98G than in the other 
cell lines, probably due to an increased sensitiv-
ity of T98G toward EGCG-mediated apoptosis. 
Das and colleagues have recently demonstrated 
that EGCG and other flavonoids are able to 
induce apoptosis in T98G cells with an increase 
in reactive oxygen species production and activa-
tion of kinases and proteases [27]. In A431 cells, 
however, EGCG-mediated apoptosis seems to 
involve other mechanisms, such as inhibition 
of NF-kB/p65, induction of DNA breaks and 
cleavage of poly(ADP-ribose) polymerase [28]. 
These various mechanisms might be respon-
sible for the differences in cytotoxicity observed 
following the same treatment on these different 
cell lines. 
In vivo, the authors demonstrated that the 
intravenous administration of EGCG encapsu-
lated within Tf-bearing vesicles resulted in com-
plete tumor eradication for 40% of B16-F10 and 
A431 tumors. This work corresponds to a major 
improvement of the therapeutic efficacy of this 
drug for the treatment of distant tumors. Previous 
in vivo studies demonstrated that EGCG admin-
istered orally was able to inhibit the proliferation 
of uterine leiomyoma cells and PC-3 tumors in 
nude mice [29,30]. Similarly, the intraperitoneal 
administration of EGCG, free or encapsulated 
in nanoparticles, also led to a significant decrease 
in tumor volume compared with control mice 
[1,22]. Combinatorial approaches using orally 
administered EGCG and anticancer drugs, such 
as doxorubicin and erlotinib, led to a decreased 
tumor volume [31]. Orally administered EGCG 
and luteolin synergistically increased apoptosis 
in both Tu212 head and neck and A549 lung 
cancer cell lines, leading to tumor stabilization 
for Tu212 [32]. 
To the authors’ knowledge, it is the first time 
that the intravenous administration of EGCG 
encapsulated in a tumor-targeted delivery sys-
tem was able to induce tumor regression, and 
even lead to complete tumor suppression for 40% 
of the treated animals on the two tested tumor 
types. It is also important to note that EGCG 
can exert an anticancer effect in vivo, not only 
as a tumor growth inhibitor or as a therapeutic 
adjuvant, as previously described, but also by 
itself, provided it is efficiently targeted to the 
tumors.
Conclusion
In this study, the authors demonstrated for the 
first time that the green tea polyphenol, EGCG, 
encapsulated in a tumor-targeted delivery sys-
tem can lead to complete tumor eradication for 
40% of the tested tumors following intravenous 
administration. 
The encapsulation of EGCG in Tf-bearing 
vesicles significantly increased the cellular uptake 
of the drug and therefore led to an increased 
in vitro therapeutic efficacy, compared with that 
observed with the drug in solution.
In vivo, this tumor-targeted formulation led to 
complete tumor disappearance in 40% of A431 
and B16-F10 tumors, tumor regression in 30% 
of A431 tumors and 20% of B16-F10 tumors 
at the end of the experiment. Animal survival 
was improved by more than 20 days compared 
with controls. By contrast, 100% of both tumor 
types treated with controls were growing. The 
treatments were well tolerated by the animals.
The green tea polyphenol, EGCG, encapsu-
lated in Tf-bearing vesicles is, therefore, a highly 
promising strategy for antitumor therapy and 
should be investigated further to optimize the 
anticancer therapeutic effect of this drug. 
Table 1. Cytotoxicity of epigallocatechin-3-gallate encapsulated in transferrin 
vesicles, control vesicles or free in solution in A431, B16-F10 and T98G cells.
Cell line Transferrin vesicles 
IC50 (µg/ml) 
(mean ± SEM)
Control vesicles 
IC50 (µg/ml) 
(mean ± SEM)
Free EGCG 
IC50 (µg/ml) 
(mean ± SEM)
A431 1.41 ± 0.17 2.74 ± 0.39 >25
B16-F10 0.96 ± 0.03 2.66 ± 0.57 >25
T98G 0.36 ± 0.05 1.44 ± 1.01 >25
Values are expressed as IC
50
 values (n = 15). 
EGCG: Epigallocatechin-3-gallate; SEM: Standard error of the mean.
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Future perspective 
While EGCG has been widely studied for 
its cancer chemopreventive and therapeutic 
potential, little has been done regarding the 
tumor-specific delivery of this drug follow-
ing intravenous administration. In this study, 
the authors demonstrated for the first time 
that EGCG encapsulated in a tumor-targeted 
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Figure 4. In vivo therapeutic efficacy of intravenously administered epigallocatechin-3-gallate formulations on A431 
tumors. (A) Tumor growth studies in a mouse A431 xenograft model after intravenous administration of transferrin vesicles 
encapsulating epigallocatechin-3-gallate (10 µg/injection); controls: control vesicles encapsulating EGCG, EGCG solution and untreated 
tumors (n = 10). (B) Variations of the animal bodyweight throughout the treatment. Error bars represent standard error of the mean. 
(C) Overall tumor response to treatments at the end of the study (day 30). (D) Time to disease progression. The y-axis gives the 
proportion of surviving animals over time. Animals were removed from the study once their tumor reached 12 mm in diameter.  
EGCG: Epigallocatechin-3-gallate; Tf: Transferrin. 
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delivery system was able to induce tumor regres-
sion and even tumor suppression for 40% of the 
treated tumors. It is hoped that these promis-
ing results will lead to the development of this 
field of research. The encapsulation of EGCG in 
tumor-targeted delivery systems should be fur-
ther studied in order to reveal the full anticancer 
potential of this drug.
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Figure 5. In vivo therapeutic efficacy of intravenously administered epigallocatechin-3-gallate formulations on B16-F10 
tumors. (A) Tumor growth studies in a mouse B16-F10 tumor model after intravenous administration of Tf vesicles encapsulating EGCG 
(10 µg/injection); controls: control vesicles encapsulating EGCG, EGCG solution and untreated tumors (n = 10). (B) Variations of the 
animal bodyweight throughout the treatment. Error bars represent standard error of the mean. (C) Overall tumor response to treatments 
at the end of the study (day 30). (D) Time to disease progression. The y-axis gives the proportion of surviving animals over time. Animals 
were removed from the study once their tumor reached 12 mm in diameter. 
EGCG: Epigallocatechin-3-gallate; Tf: Transferrin. 
Nanomedicine (2013) 8(2)190 future science group
ReseaRch aRticle Lemarié, Chang, Blatchford et al.
As EGCG combined with the polyphenols 
resveratrol and tocotrienol has been shown to 
elicit synergism in suppressing cell prolifera-
tion [33], the co-entrapment of these drugs in 
Tf-bearing vesicles to optimize the therapeutic 
effect is currently being worked on. 
In a more general context, this study showed 
that a drug, previously known as a tumor 
growth inhibitor and as a therapeutic adjuvant, 
could have a therapeutic effect when targeted 
to tumors. It is therefore expected that some 
other molecules previously unable to reach 
the disease site may be given a second thera-
peutic chance as anticancer drugs following 
entrapment within efficacious tumor-targeted 
delivery systems. 
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Figure 6. Bioluminescence imaging of the tumoricidal activity of epigallocatechin-3-gallate 
encapsulated in transferrin vesicles in a mouse B16-F10-luc tumor model. Controls: control 
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Executive summary
Introduction
  The green tea polyphenol, epigallocatechin-3-gallate (EGCG), has promising anticancer properties in vitro and in vivo.
  Its use is limited by its failure to reach tumors in a specific way after intravenous administration at concentrations high enough to allow 
for a therapeutic use.
In vitro therapeutic efficacy
  In vitro, the encapsulation of EGCG in transferrin-bearing vesicles improved the antiproliferative efficacy of the drug on A431, T98G and 
B16-F10 cells.
In vivo tumoricidal activity
  In vivo, the intravenous administration of EGCG encapsulated in transferrin-bearing vesicles resulted in an entire tumor disappearance in 
40% of B16-F10 and A431 tumors. Consequently, the survival of the treated mice was increased by more than 20 days compared with 
controls. 
Conclusion
  Transferrin-bearing vesicles are highly promising for the delivery of EGCG to cancer cells in vitro and in vivo, and should be further 
investigated to optimize the anticancer therapeutic effect of this drug. 
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